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Abstract: Primary infection with varicella zoster virus (VZV) causes chickenpox (varicella) 
after which virus becomes latent in cranial nerve, dorsal root and autonomic ganglia along the 
entire neuraxis. Virus may later reactivate, causing shingles (zoster), characterized by pain 
and rash restricted to 1–3 dermatomes. More than 40% of zoster patients over age 60 develop 
postherpetic neuralgia (PHN), pain that persists for months to years. The socioeconomic impact 
of primary varicella infection has been lessened by introduction of VZV vaccine for children. 
However, the effect of childhood vaccination on the incidence of zoster is unknown. Virus 
reactivation correlates with waning cell-mediated immunity (CMI) to VZV with normal aging. 
Adults exposed to children with varicella may have a boost in CMI to VZV. For at least sev-
eral more decades, the incidence of zoster may increase as the elderly population grows. The 
anticipated increase in zoster burden of illness in future decades was a major impetus for the 
Shingles Prevention Study, a prospective, double-blind, placebo-controlled trial of attenuated 
VZV vaccine to prevent zoster in older adults. This review discusses clinical and virological 
aspects of zoster and its complications, current treatment options, and VZV vaccine develop-
ment along with its future role in disease prevention. 
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Introduction
Varicella zoster virus (VZV) is a neurotropic herpesvirus that infects nearly all 
humans. Primary infection causes chickenpox (varicella) after which virus becomes 
latent in cranial nerve, dorsal root and autonomic ganglia along the entire neuraxis. 
Decades later, a declining VZV-speciﬁ  c cell-mediated immunity (CMI) allows virus 
to reactivate, resulting in shingles (zoster), characterized by pain and rash restricted 
to 1–3 dermatomes. The increasingly widespread use of an attenuated varicella vac-
cine has nearly eradicated chickenpox in areas of the world where vaccination is 
employed. The success of a varicella vaccine combined with data showing a boost in 
CMI to VZV in vaccinated VZV-seropositive adults led to the Shingles Prevention 
Study (SPS), which revealed that vaccination of VZV-seropositive men and women 
over the age of 60 reduced the incidence of zoster and postherpetic neuralgia (PHN). 
This review discusses the epidemiology and pathogenesis of zoster, with a focus on 
the potential of a VZV vaccine to prevent zoster and reduce the burden of illness on 
the patient and on society. 
Epidemiology and pathogenesis
Zoster affects approximately 1 million people per year in the United States alone 
(Oxman et al 2005), with millions more worldwide. No genetic predisposition has 
been identiﬁ  ed (Blackwelder et al 1982). The frequency of zoster is proportionally 
related to the incidence of chickenpox which is independent of socioeconomic status, 
population density, gender or ethnic origin (Nagasako et al 2003). Exposure of adults 
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to infected children is thought to provide repeated boosts in 
immunity to VZV (Thomas et al 2002). Thus, it is possible 
that chickenpox vaccination, which has reduced the inci-
dence of childhood varicella, will increase the incidence 
of zoster in adults (Brisson et al 2000, 2002; Goldman 
2005). At the same time, childhood vaccination may result 
in a lower virus burden in latently infected ganglia, reducing 
the overall incidence of zoster in adults who were vaccinated 
in childhood (Arvin and Greenberg 2006). Only time will 
tell which effect or combination of effects will be important. 
However, the answer may never be known if recipients 
of zoster vaccine (now approved by the FDA) results in a 
decreased incidence of zoster.
Zoster is the result of reactivation of latent VZV and trans-
port to basal epidermis of skin where infected cells produce 
conditions favoring virus spread, such as the downregulation 
of interferon-alpha and lymphocyte adhesion molecules (Ku 
et al 2004).  As infected cells die, interferon-alpha is induced 
in the neighboring cells which slows the spread of VZV and 
enhances T-cell clearance of the infection (Chen et al 2004; 
Nikkels et al 2004).  An association between zoster and the 
immune system has been recognized for decades (Miller and 
Brunell 1970).  Zoster occurs most commonly in elderly and 
immunocompromised individuals, reflecting a decreased 
number of circulating VZV-responsive CD4+ T cells (Hayward 
and Herberger 1987; Hayward et al 1991).  Unless adults are 
vaccinated, the incidence of zoster is likely to increase in the 
growing elderly population, who experience a natural decline 
in CMI to VZV (Miller 1980; Berger et al 1981) and will have 
fewer immune boosts from exposure to sick children (Brisson 
et al 2000; Brisson et al 2002; Goldman 2005).  Further, the 
number of patients treated with immunosuppressive drugs and 
radiotherapy is increasing, as well as the number of immuno-
suppressed organ transplant recipients.  Finally, the number of 
AIDS patients increases every year, and they have the highest 
incidence of zoster, including recurrent and more protracted 
zoster (Gilden et al 1994). Overall, zoster may be viewed in 
the context of a continuum in immunodeﬁ  cient individuals, 
ranging from a natural decline in VZV-speciﬁ  c CMI with age, 
to more serious immune deﬁ  cits seen in cancer patients and 
transplant recipients, and ultimately in patients with AIDS 
(Gilden et al 2003).
Burden of illness (BOI)
The zoster BOI is felt by both the patient and society.   
Although pain and rash usually occur within a few days of 
each other, the rash of zoster may be preceded by pain for 
as long as 100 days (Gilden et al 1991; Fristad et al 2002).   
The pain of acute zoster typically lasts 4–6 weeks and ad-
versely affects activity, mood, interpersonal relationships, 
sleep and general quality of life (Oster et al 2005; Scott et al 
2006). More than 40% of zoster patients over age 60 years 
experience pain for months or years after resolution of rash 
(PHN) (Bowsher 1994). The cause of PHN is unknown. Cor-
relative clinical, pathological and virological studies support 
the hypothesis that PHN may result from persistent virus 
infection in ganglia (reviewed in Gilden et al 2005).
The zoster BOI to society is reﬂ  ected in the cost of lost 
productivity and added cost of providing clinical care.  Cur-
rent estimates of zoster in the United States are from 600,000 
to 1,000,000 new cases per year (Goldman 2005, Insinga et al 
2005). The estimated mean healthcare provider cost alone, 
excluding the additional burden of PHN, is $280 per zoster 
case (Goldman 2005).
Varicella vaccine
Attenuated Oka varicella vaccine was developed by 
passaging VZV isolated from a 3-year-old boy 11 times 
in human embryonic lung (HEL) cells, 6–7 times in 
guinea pig embryo (GPE) cells and 2–6 times in human 
diploid WI-38 cells (Takahashi et al 1974).  Vaccine 
virus effectively induced an immune response without 
clinical disease in 23 normal susceptible children; the 
minimum dose required was 200 plaque-forming units 
(PFUs) (Asano et al 1975; Takahashi et al 1975).  Merck 
laboratories passaged the virus further though different 
cell lines including HEL, GPE, WI-38, and MRC-5 human 
diploid fibroblasts to produce the commercial varicella 
vaccine (Varivax) which contains 1350 PFUs in 0.5 ml 
of sterile water (Ellis 1995). After 15 years of testing in 
the US, Japan, Canada and Europe, varicella vaccine was 
approved for children at high risk for developing severe 
and even fatal varicella (Gershon 1987). The protective 
efficacy of the vaccine virus in normal healthy children 
during the varicella season was determined to be 100% 
(491 children) in the first year and 96% (163 children) 
in the second year by a double-blind placebo-controlled 
study (Kuter et al 1991). In 1995, live attenuated varicella 
vaccine was licensed by the FDA for use in individuals 
at least 12 months of age who have not had varicella.   
Like wild-type virus, Oka/Merck vaccine virus becomes 
latent in ganglia and can reactivate to produce zoster 
(Gelb et al 1987; Brunell and Argaw 2000). To date, the 
rate of zoster in vaccinated children is comparable to that 
in healthy children after natural varicella (http://www.
varivax.com). Therapeutics and Clinical Risk Management 2007:3(4) 635
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Characteristics of Oka vaccine
Compared to wild-type VZV, Oka vaccine virus produces 
smaller plaques in HEL cells at 39 °C and grows better at 
34 °C (Breuer 2001). In tissue culture, Oka vaccine virus is 
less efﬁ  cient than wild-type VZV in spreading from infected 
T-cells in tissue culture to melanoma cells (Soong et al 2000). 
While the DNA sequence of parental Oka and vaccine strains 
of VZV is predominantly similar, 63 mutations in the latter 
have been detected (LaRussa et al 1992; Hawrami and Breuer 
1997; Gomi et al 2002; Cohrs et al 2006). DNA sequence 
analysis of virus recovered from zoster patients who had 
been vaccinated earlier showed that nucleotide changes in 
Oka vaccine virus remained stable after passage through 
humans (Argaw et al 2000). 
Cell-mediated immunity (CMI) 
and humoral immunity to varicella 
vaccine
Vaccination of adults with the Oka/Merck vaccine virus 
produces both antibody and CMI responses within 3 months 
(Hayward et al 1992).  Signiﬁ  cantly, CMI to VZV is more 
important than humoral immunity and correlates with protec-
tion from virus reactivation (Zoulek 1985).  In adults, two 
doses of vaccine are required to produce the same magni-
tude of CMI response produced with one dose of vaccine 
in children, likely reﬂ  ecting the natural decline with age in 
the ability of T-cells to recognize VZV antigens (Arvin and 
Gershon 1996). In adults, periodic exposure to varicella 
probably boosts both CMI as well as the humoral response to 
VZV. The maintenance of high antibody values in vaccinees 
is explained by endogenous reactivation of the Oka vaccine 
virus (Krause and Klinman 2000).
Efﬁ  cacy (short- and moderate-
term), safety and tolerability
A randomized single-blind study using different doses 
(280–28,000 pfu) of live vaccine in 95 healthy VZV-sero-
positive adults, showed that virus was well-tolerated over a 
wide range of viral dosage. At 72 hours after vaccination, 
localized reactions at the site of inoculation were found 
with doses >2800 PFU (Sperber et al 1992). In 419 children 
and adolescents who were given a booster dose (3300 pfu) 
of vaccine 6 years after primary immunization, no serious 
adverse events were encountered; 180/298 (60%) of the 
vaccinees developed a 4-fold rise in VZV antibody titers, 
and CMI to VZV increased (Watson et al 1995). A 12-year 
follow-up of vaccinated adults who had previously been 
seronegative or had lost detectable antibody over a 3-month 
period showed protection from chickenpox (Ampofo et al 
2002). Grose (2005) has suggested that genetic variability 
among wild-type VZV strains may account for differences in 
the effectiveness of Oka vaccine in Japanese and American 
children, but these differences have not yet been examined 
among adults receiving the zoster vaccine.
Zoster vaccine
The VZV vaccine studies and scope of the zoster problem set 
the stage for the large-scale double-blind, placebo-controlled, 
multi-center Shingles Prevention Study (SPS) to determine 
the effect of VZV vaccination in preventing zoster (Oxman 
et al 2005). Otherwise healthy adults age 60 or older (median 
age 69 years) were vaccinated with placebo or an attenu-
ated Oka/Merck-VZV vaccine containing 18,700 to 60,000 
PFUs of virus, considerably greater than the approximately 
1350 PFUs in the Oka/Merck-VZV vaccine administered to 
American children since 1995. More than 38,000 recipients 
of the “zoster vaccine” were followed closely for 3 years. 
The incidence of zoster in the placebo group was 11.1 per 
1000-person years. This ﬁ  gure approximates the results of 
an epidemiological survey performed a decade ago, which 
revealed zoster exceeding 10 cases per 1000-person years 
among individuals older than 75 years (Donahue et al 1995). 
The effect of zoster vaccine was impressive. Compared to 
placebo, vaccination reduced the incidence of shingles by 
51%, the incidence of PHN by 66% and the BOI by 61%. 
Like the live childhood varicella vaccine, live zoster 
vaccine appears to be safe and effective clinically. Overall, 
serious adverse effects (SAEs) and deaths occurred in 1.4% of 
both vaccine and placebo recipients. In a subset of more than 
6000 subjects who kept daily diaries of minor adverse effects 
for 42 days, injection site erythema, pain or tenderness, swell-
ing and pruritis were reported in 48% of vaccine recipients 
compared to 16% of placebo recipients. In the same subset, 
SAEs were signiﬁ  cantly more frequent (p = 0.03) in 1.9% of 
vaccine recipients compared to 1.3% of placebo recipients, 
although no speciﬁ  c SAE emerged in vaccine recipients. The 
relative impact of these side effects on the elderly (age ≥ 70) 
compared to younger patients was not examined but might 
be important in future analyses, since the at-risk popula-
tion over age 70 is projected to increase substantially in the 
coming decades. Although the Oka/Merck VZV vaccine on 
rare occasions unmasks a childhood immunodeﬁ  ciency dis-
order, no cases of disseminated zoster were reported which 
might have been attributed to zoster vaccine in a person with 
undiagnosed lymphoma, leukemia or the like.Therapeutics and Clinical Risk Management 2007:3(4) 636
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Quality of life
Various approaches, many of which take into account pain 
severity as measured on the 0 to 10 Likert scale (0 = no pain, 
10 = severe pain), have been taken to measure quality of 
life in patients with zoster and PHN. The Zoster Brief Pain 
Inventory (ZBPI) is an assessment containing zoster-speciﬁ  c 
modiﬁ  cations to the more general Brief Pain Inventory, a 
widely used questionnaire to evaluate pain. The ZBPI is 
designed to capture zoster pain severity and interference 
with functional status in seven spheres of daily life: general 
activity, mood, walking, work, relations with others, sleep 
and enjoyment of life. Subjects rate their pain severity on a 
0–10 scale when it is at its worst, least, average, and at the 
time of questionnaire completion. Functional status in all 
seven spheres is assessed using the same 0–10 scale. The 
ZBPI worst pain score correlates well with results from the 
McGill Pain Questionnaire and SF-12, two other commonly 
used surveys for pain, quality of life and daily living activities 
(Coplan et al 2004).
When the ZBPI worst pain score is plotted against dura-
tion of pain, the area under the curve provides a severity-
duration measurement that reﬂ  ects zoster BOI and is sensitive 
to changes in incidence, severity and duration (Coplan et al 
2004). The resulting BOI measurement correlates favorably 
with data collected from other commonly used question-
naires, including pain measures from the McGill Pain Inven-
tory, activity of daily living measures from the Zoster Impact 
Questionnaire and ZBPI, and quality of life measures from 
the EuroQoL and mental and physical health summaries of 
the SF-12. The ZBPI and BOI score were the measurement 
tools chosen to evaluate the effect of zoster vaccine in older 
individuals (Oxman et al 2005).
Management options
Treatment of herpes zoster with antiviral medication (acy-
clovir, famcyclovir or valacyclovir) within 72 hours of the 
onset of rash results in faster healing and a reduced period 
of pain (Tyring et al 1995, 2000; Wood et al 1996). Of the 
three drugs, only acyclovir is available generically, but its 
lower cost must be weighed against its cumbersome ﬁ  ve 
times per day dosing, which may result in reduced patient 
compliance. Famciclovir and valacyclovir are more expen-
sive, but are preferred by many physicians because of their 
more convenient three times per day dosing. The effect of 
antiviral treatment started more than 72 hours after the onset 
of rash has not been studied.
The use of corticosteroids for herpes zoster is contro-
versial. One study showed that a 3-week course of oral 
treatment may reduce pain after 2 weeks but with no sig-
niﬁ  cant difference from placebo after 3 weeks (Wood et al 
1994). In another study, quality of life at 30 days was better 
with corticosteroid treatment (Whitley et al 1996); however, 
only adults without signiﬁ  cant medical problems such as 
diabetes or high blood pressure were enrolled, resulting in 
a disproportionately healthy study population. Thus, those 
results may not be widely applicable, especially for elderly 
patients with chronic diseases that may predispose them to 
zoster. Corticosteroids have no effect on the incidence or 
severity of PHN. The decision to treat must be balanced 
against the known risks of corticosteroid therapy.
Early gabapentin treatment during a zoster attack results 
in less acute pain and may reduce the incidence and sever-
ity of PHN (Berry and Petersen 2005). Amitriptyline may 
have a similar effect (Bowsher 1997). Both medications are 
postulated to reduce “central sensitization” of pain pathways, 
resulting in stabilization of the ﬁ  ring threshold of spinal cord 
neurons in response to afferent sensory stimuli. More clinical 
studies are needed to evaluate the role of early gabapentin 
and amitriptyline in zoster to prevent PHN. 
Despite antiviral treatment, many shingles patients 
develop PHN, the most common complication of zoster. 
Treatment options include opioid analgesics, tricyclic 
antidepressants, anticonvulsants, topical medications and 
more invasive therapies such as intrathecal corticosteroids 
or ganglionic blockade. Based on evidence from Class I or 
Class II clinical studies, the American Academy of Neurol-
ogy currently recommends the following medications as 
moderately or highly effective in the treatment of PHN: 
gabapentin, pregabalin, tricyclic antidepressants, controlled-
release oxycodone or morphine sulfate, and lidocaine patch 
(Dubinsky et al 2004). These medications were considered 
to have low levels of side effects. Treatments such as aspirin-
based creams or ointments, topical capsaicin, and intrathecal 
methylpredisolone also have clinical trial data supporting 
their use, but their efﬁ  cacy is lower than the ﬁ  rst-line agents 
or their side effects are more limiting. Other treatments such 
as dorsal root entry zone or stellate ganglion blocks, laser 
irradiation, and acupuncture are not effective compared to 
placebo or have only Class IV data supporting their use. 
In clinical practice, many PHN sufferers are refractory 
to available therapy. Patient satisfaction, especially among 
older individuals, is further compromised by intolerable side 
effects such as confusion, dizziness, sedation, nausea or other 
gastrointestinal disturbances. The difﬁ  culty of managing 
PHN indicates the need for a greater understanding of the 
disease so that treatment can be targeted at the underlying Therapeutics and Clinical Risk Management 2007:3(4) 637
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mechanism(s) of pain. While correlative clinical, virological 
and pathological data suggest that persistent low-grade VZV 
activity contributes to PHN pain (reviewed in Gilden et al 
2005), and preliminary clinical data on the effect of treatment 
with intravenous acyclovir followed by oral valacyclovir in 
patients with PHN suggest that pain can be reduced with 
antiviral therapy, corroboration of these ﬁ  ndings awaits larger 
double-blind, randomized, placebo-controlled studies.
Conclusion
Zoster vaccine is currently recommended for healthy adults 
over age 60. One unanswered question is the future risk of 
zoster in middle-aged adults who were vaccinated in child-
hood with attenuated VZV compared to the current risk 
for middle-aged adults, most of whom have had wild-type 
VZV infection. By 2047, most middle-aged Americans will 
have received VZV vaccine in childhood. Like wild-type 
VZV, Oka-VZV vaccine virus becomes latent in ganglia 
(Gelb et al 1987). If the virus burden is less in ganglia of 
adults who were vaccinated in infancy, then the incidence 
of zoster may be reduced compared to those who had 
naturally occurring chickenpox. On the other hand, CMI 
to VZV in vaccine recipients may wane over time due to 
fewer exposures to children with varicella. The desirability 
of mass childhood varicella vaccination is beyond the scope 
of this review; however, the impact of this practice on 
adults may be problematic, at least in the ﬁ  rst 50–70 years 
of a vaccination program (Thomas et al 2002; Brisson et al 
2003; Gidding et al 2005; Volpi 2005). The loss of normal 
boosts to immune responsiveness through exposure to sick 
children would support the need to vaccinate middle-aged 
adults. Zoster vaccine would certainly increase CMI to 
VZV in such individuals, and the boost would likely last 
for decades. 
An earlier discussion of the cost-effectiveness of vac-
cination (Gilden 2005) emphasized that the SPS used a 
disease-speciﬁ  c measure, the zoster BOI (Coplan et al 2004) 
to assess severity of illness among study participants. Herpes 
zoster BOI scores correlated with Quality Adjusted Life Years 
(QALYs), the standard denominator of cost-effectiveness 
(Weinstein et al 1996). The cost-effectiveness of vaccine 
will depend on its price. For consumers who pay for child-
hood varicella vaccine (Varivax™), the price is $50–$100 
(the sum of the cost of vaccine plus the visit fee). Since the 
zoster vaccine contains more virus, it might cost more.  The 
durability of zoster vaccine effectiveness and need for booster 
shots will require further examination (Levin et al 1998). One 
model suggests that two doses of vaccine at ages 50 and 70 
may most effectively reduce the number of cases of shingles 
(Chapman et al 2003).
Nevertheless, in the SPS, a single dose of zoster vaccine 
was probably highly cost-effective (in the range of $2,000/
QALYs gained, even assuming a vaccine cost of $500). 
This admittedly rough estimate does not include the cost of 
complications related to vaccination or provider time required 
to administer it. However, $2000/QALY is still likely to 
underestimate cost-effectiveness, since gains in quality of 
life experienced by vaccine recipients are likely to persist 
beyond the 3 years of the study. Even if two vaccinations 
were administered per person, the vaccine should still fall 
well below the traditional cutoff of $50,000/QALY used to 
evaluate new therapies, and would appear to be at least as 
cost-effective as other currently used vaccines (Prosser et al 
2004). Zoster vaccine could eventually even be cost-saving, 
though the complex interaction between varicella vaccination 
and the incidence of herpes zoster may erode these savings 
in the near-term (Gidding et al 2005).
The high incidence of zoster found in the SPS placebo 
group points to an urgent need for effective therapy. While 
oral antiviral medication shortens the duration of zoster and 
analgesic medications provide some relief of pain, “an ounce 
of prevention is worth a pound of cure.” Once rash does oc-
cur, the effect of rapid and aggressive antiviral or analgesic 
therapy within the ﬁ  rst 72 hours may reduce or even prevent 
PHN. Comparisons of the cost effectiveness of vaccination 
and early aggressive treatment of rash will be invaluable in 
formulating public health recommendations (Volpi 2005). 
The long-term public health effect of zoster vaccination will 
need further study, those over age 85 whose CMI response 
to VZV is likely to be less robust than in people 20–25 
years younger. This is important because the Census Bureau 
projects that by the year 2050, there will be more than 21 
million Americans 85 years of age or older (http://www.
census.gov/ipc/www/usinterimproj/natprojtab02a.pdf). 
Vaccination would allow not only a further determination of 
possible risk to recipients, but also an estimation of vaccine 
effectiveness in the oldest old. Hopefully, “zoster vaccine” 
will reduce or eradicate zoster and its related complications, 
just as measles vaccine has eradicated not only measles, but 
also measles post-infectious encephalomyelitis and subacute 
sclerosing panencephalitis in geographical regions where 
vaccination is used. 
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